Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices

Bristol Myers Squibb, Novo Nordisk, and Ipsen Biopharmaceuticals notified 340B covered entities this week about refunds for charges above 340B ceiling prices.

Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.

Please Login or Become a Paid Subscriber to

Read More »

Groups and Individual Health Care Providers Grapple with BMS’s New 340B Contract Pharmacy Policy

Individual 340B covered entities are deciding how to respond to the multi-point 340B contract pharmacy policy that Bristol Myers Squibb (BMS) released last Friday.

Groups that represent 340B hospitals yesterday slammed the multi-point 340B contract pharmacy policy that Bristol Meyers Squibb (BMS) released last Friday.

Please Login or Become a Paid Subscriber to View this Content

Read More »

BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program

BMS yesterday imposed restrictions on 340B pricing on most of its covered outpatient drugs, while liberalizing its policy on access to 340B pricing on its expensive cancer drugs Revlimid, Pomalyst, and Thalomid.

Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.

Please Login or Become a Paid

Read More »

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.

Read More »

Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev

Boehringer Ingelheim extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Please Login or Become a Paid Subscriber to View this

Read More »

More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling

850+ hospitals in the 340B program sent the HHS secretary a letter yesterday asking the government to appeal a judge’s 340B contract pharmacy ruling.

Just over 850 hospitals in the 340B program asked the federal government yesterday to appeal a judge’s Nov. 5 ruling that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and others use contract pharmacies. They

Read More »

Provider Groups Pan Lilly’s 340B Contract Pharmacy Policy Change

Groups representing health care providers have panned Lilly's recent 340B contract pharmacy policy change.

Groups representing 340B health centers, Ryan White clinics, and hospitals panned drug manufacturer Lilly’s recent decision to amend its prohibition on 340B pricing when providers use contract pharmacies to dispense drugs to patients.

Please Login or

Read More »

Is There a New 340B Stakeholder Group for Pharma Companies?

A new infographic by a drug industry consultant indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.

Please Login or Become a

Read More »

Breaking News: Lilly Will Honor Unlimited 340B Contract Pharmacy Arrangements in Exchange for Entities’ Claims Data

Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders.

Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders, a company spokesperson said late today.

Read More »

Influential House Lawmaker and Rural Hospitals Upset About J&J’s 340B Orphan Drug Policy Change

Johnson & Johnson is ending voluntary 340B drug discounts on Remicade and other Janssen brand orphan drugs to rural and free-standing cancer hospitals.

Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,”

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report